The Future of Care: Bipolar Disorder

Uncategorized

Apr 20

Written By

Bipolar disorder is one of the most devastating conditions in mental health - and one of the most neglected by the healthcare system. More than 7 million Americans live with some form of bipolar disorder, and roughly 46 million people worldwide. The condition has a strong genetic component¹, interacts with neurobiological triggers, and typically first appears around age 25³. It's not rare yet the gap between how well we could treat it and how well we actually do is staggering.

The system fails bipolar patients

Consider the patient journey. On average, someone with bipolar disorder waits 5 to 10 years to receive a correct diagnosis⁴. 69% are initially misdiagnosed - usually told they have regular depression⁵ - and prescribed medications that can actually make bipolar worse. Even after diagnosis, studies found that patients are symptomatic nearly half the time⁶.

The numbers cascade from there. Suicide risk is roughly 20 times the general population⁷, with up to half of all patients attempting suicide in their lifetime. ⁸75% will be hospitalized at some point. The total economic cost in the U.S. reaches $195 billion per year - and nearly 80% of that comes not from medical bills but from lost productivity, disability, and shortened lives⁹ .

Why is care so poor? The main culprit is fragmentation. A typical bipolar patient sees a psychiatrist for a 15-minute medication check, a separate therapist who likely has no bipolar-specific training, and receives no structured psychoeducation - despite research showing that psychoeducation alone can reduce time spent in mood episodes from 30% to 8% over five years¹⁰. The tools exist but the system doesn’t connect them.

The toolkit is better than ever - if patients can access it

The major NIMH-funded STEP-BD trial showed that patients receiving structured psychotherapy plus medication achieved 64% recovery rates compared to 52% with medication alone¹⁴. Three modalities stand out: Cognitive Behavioral Therapy (CBT) adapted for bipolar, Dialectical Behavioral Therapy (DBT), and Interpersonal and Social Rhythm Therapy (IPSRT), created by Ellen Frank to target the circadian rhythm disruptions that trigger mood episodes¹⁶.

While most in the mental health field are familiar with CBT and DBT, IPSRT remains underutilized in clinical settings. Interpersonal and Social Rhythm Therapy (IPSRT) targets what may be the most underappreciated driver of bipolar relapse: circadian disruption.

The premise is straightforward. Stressful life events and irregular daily routines destabilize sleep-wake cycles, meal timing, and activity patterns, which in turn trigger mood episodes in biologically vulnerable individuals. IPSRT combines interpersonal psychotherapy techniques with structured behavioral work on stabilizing these daily rhythms. In Frank’s landmark RCT of 175 patients with bipolar I, those assigned to IPSRT during the acute treatment phase survived significantly longer without a new affective episode over two years of follow-up.

Pharmacotherapy options for bipolar disorder have also expanded enormously. Lithium remains a cornerstone, with unique anti-suicide properties that no other medication matches.¹¹ A full range of second-generation antipsychotics and the recently approved lumateperone (the first drug indicated for both bipolar I and bipolar II depression)¹² - have given clinicians options that didn’t exist 20 years ago. Pipeline drugs targeting entirely new mechanisms are advancing through late-stage trials.¹³Today, there are over 20+ drugs that are prescribed to manage bipolar disorder.

Digital tools - smartphone-based mood tracking, wearable data, digital phenotyping - are adding a new layer of passive monitoring, though the technology is still maturing¹⁷

The rise of condition-specific platforms

The broader mental health startup landscape is evolving rapidly. It is now generally understood that condition-specific platforms have the potential to outperform generalist platforms with regards to clinical outcomes.

Yet until recently, nobody has taken on bipolar disorder. It’s arguably the highest-burden psychiatric condition without a dedicated, scaled care platform.

Enter Sway Health, the first telehealth company built exclusively around bipolar.

“Bipolar patients lose years, sometimes decades, between diagnosis and stability. Lost jobs. Broken relationships. Diminished life. We’ve accepted this as normal. It isn’t. That’s why we built Sway - with the goal of getting patients to stability in months rather than years.” says Co-Founder and Board Chair Saki Georgiadis (20 years lived experience with bipolar, incubated 4 mental health startups)

Sway trains and deploys individual clinicians who deliver medication management, psychotherapy, and psychoeducation in a single integrated session. Their therapy protocol is proprietary - a blend of CBT, DBT, and IPSRT codified in a proprietary clinical manual and pharmacology guide.

The early results stand out. Sway reported a 37% reduction in depression scores and 40% reduction in mania scores after just 30 days of treatment, with improvements sustaining over time. These results compare favorably with NOCD and Equip Health published benchmarks.

Results from a preliminary clinical analysis conducted in March 2026. Green indicates both clinically and statistically significant results; gray indicates neither.

“Far too many patients with bipolar disorder fall through the cracks of our medical system not because existing interventions don’t work, but because the process of providing care is disjointed and confusing to patients and their families. Sway’s integrated approach bridges those gaps and creates a single and reliable source for care,” (Dr Samoon Ahmad - Chief Medical Officer of Sway Health)

The company has delivered over 1,300 appointments across Illinois, Ohio, and Virginia, with insurance contracts already in place with BCBS, Aetna, Cigna, Optum, and various Medicaid MCOs.

The team is led by Co-Founder and CEO Vibha Puri (BCG, Stanford GSB) and COO Christy Maselli, the first non-founder hire at Grow Therapy who scaled the company to over 20,000 providers. CMO Dr. Samoon Ahmad brings three decades of mood disorder expertise from NYU and as the ex-unit Chief of Bellevue inpatient²². Dr. Ellen Frank - the scientist who invented²³ IPSRT, the gold-standard psychotherapy for bipolar²⁴ - serves as clinical advisor.

What comes next

The pattern is now familiar. A high-burden condition with fragmented care and a massive payer incentive to improve outcomes. Startups focused on OCD, eating disorders, and opioid use disorder have attracted billions in investment and treated hundreds of thousands of patients. Bipolar disorder - with its $195 billion annual burden²⁷, its 7 million affected Americans, and its enormous treatment gap - is ripe for tech-enabled healthcare.

Sway Health is the nation’s first specialized virtual care platform for bipolar disorder that integrates medication management, psychotherapy, and psychoeducation under a single clinician, rather than fragmenting care across disconnected providers. 7M+ Americans live with bipolar disorder, representing a $14B market. Sway is live in Illinois, Ohio, and Virginia with contracts across major payers including BCBS, Aetna, Cigna, Optum, and Medicaid MCOs. Notable advisors include Ellen Frank (the creator of IPSRT) and Andy Dunn (founder of Bonobos). Vibha Puri (CEO & Co-Founder) has grown the platform to 1000+ appointments.

Feel free to reach out to Vibha Puri (CEO & Co-Founder) at vibha@swayhealth.co with any questions or comments.

Disclosure: Shivan Bhavnani is a partner at Evio VC. Evio VC invested in Sway Health.